Literature DB >> 12225436

Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts.

Mark D Pescovitz1, Ralph Barbeito.   

Abstract

Cyclosporine (CyA) trough concentrations are poor predictors for acute rejection post-transplant. Patients were part of a randomized trial of basiliximab (n=70) vs. anti-thymocyte globulin (ATGAM) (n=65), both in combination with Neoral, mycophenolate mofetil, and steroids, undergoing first or second, cadaveric or live donor renal transplants. Whole blood samples were collected just before (C0) and at 2 h after CyA dosing on day 4 and at the end of weeks 1, 2, 4, and 8. The CyA was measured by fluorescence polarization immunoassay (TDx). Mean CyA C0 and C2 concentrations were calculated. Logistic regression analysis revealed that mean C2 level was the only predictor of acute rejection (P < or = 0.001). Higher mean C2 levels predicted lower rejection probabilities. Linear regression analysis revealed that higher mean C2 levels were not related to higher serum creatinine levels at either week 4 or 24 or to incidence of headache or tremor. The CyA C2 levels predict the frequency of rejection postrenal transplant. Target C2 levels are in the range of 1500 ng/dL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225436     DOI: 10.1034/j.1399-0012.2002.02036.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  9 in total

1.  Preprandial C2 monitoring of cyclosporine treatment in children with nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Kazunari Kaneko; Masaru Takada; Yoshiyuki Ohtomo; Shunji Akashi; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-05-26       Impact factor: 3.714

Review 2.  [Modern immunosuppression following renal transplantation. Standard or tailor made?].

Authors:  K Budde; M Giessing; L Liefeldt; H-H Neumayer; P Glander
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

Review 3.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Authors:  Krishna M Karpe; Girish S Talaulikar; Giles D Walters
Journal:  Cochrane Database Syst Rev       Date:  2017-07-21

4.  Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-10-21       Impact factor: 4.200

5.  [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].

Authors:  N Bailly; I Dunewa; P Schlattmann; P W Rieck
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 6.  Interleukin 2 receptor antagonists for kidney transplant recipients.

Authors:  Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

7.  Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period.

Authors:  Salih Kavukçu; Alper Soylu; Mehmet Türkmen; Belde Kasap; Mukaddes Gümüştekin; Hüseyin Gülay
Journal:  Pediatr Nephrol       Date:  2004-03-31       Impact factor: 3.714

8.  Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial.

Authors:  Kazumoto Iijima; Mayumi Sako; Mari Saito Oba; Shuichi Ito; Hiroshi Hataya; Ryojiro Tanaka; Yoko Ohwada; Koichi Kamei; Kenji Ishikura; Nahoko Yata; Kandai Nozu; Masataka Honda; Hidefumi Nakamura; Michio Nagata; Yasuo Ohashi; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

Review 9.  Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.

Authors:  Tulio B Abud; Antonio Di Zazzo; Ahmad Kheirkhah; Reza Dana
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.